drugset / Trial / NCT00018278

Electrophysiologic Measures of Treatment Response in Alzheimer Disease

NCT00018278

Non-randomizedCrossoverOpen-labelTreatment

Summary

The main purpose of this study is to determine the electrophysiological effects of cholinergic therapy (cholinesterase inhibitors and transdermal nicotine) in Alzheimer disease. The attempt will be to locate electrophysiological markers and predictors of cognitive and clinical treatment response.

Timeline

Start
1998-10
Primary completion
Completion
2001-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Donepezil Small molecule
Subject Nicoderm Patch Unknown Other
Subject Rivastigmine Small molecule

Indications